Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01390064 · ClinicalTrials.gov registry record · Phase 1
Vaccination of High Risk Breast Cancer Patients
A Phase 1 study, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT01390064: Completed Phase 1 study, sponsored by University of Arkansas.
NCT01390064 is a Phase 1 study that has completed, run by University of Arkansas. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01390064, a Phase 1 study, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
Objective - Determine the safety and tolerability of a peptide mimotope-based vaccine upon immunization of breast cancer subjects.
Primary Outcome
The safety and tolerability of the P10s-PADRE/MONTANIDE ISA51 VG vaccine will be determined by toxicity assessments throughout the duration of the study. Subjects will be evaluated for toxicity using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.
Interventions
- BIOLOGICAL Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2011-07 |
| Est. Completion | 2019-07 |
| Phase | Phase 1 |
What the finished NCT01390064 record still lists
NCT01390064 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG is the first listed.
NCT01390064 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01390064 about?
NCT01390064 is a clinical study titled "Vaccination of High Risk Breast Cancer Patients". Objective - Determine the safety and tolerability of a peptide mimotope-based vaccine upon immunization of breast cancer subjects.
What is the current status of trial NCT01390064?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2011-07. Estimated completion is 2019-07.
What interventions are being tested in trial NCT01390064?
The interventions under investigation include: Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG (BIOLOGICAL).
Who is sponsoring clinical trial NCT01390064?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01390064's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia